- Home
- NGVT vs DNLI Comparison
NGVT vs DNLI Comparison
Compare NGVT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGVT
- DNLI
- Stock Information
- Founded
- NGVT 1964
- DNLI 2013
- Country
- NGVT United States
- DNLI United States
- Employees
- NGVT N/A
- DNLI N/A
- Industry
- NGVT Major Chemicals
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NGVT Industrials
- DNLI Health Care
- Exchange
- NGVT Nasdaq
- DNLI Nasdaq
- Market Cap
- NGVT 2.1B
- DNLI 2.1B
- IPO Year
- NGVT N/A
- DNLI 2017
- Fundamental
- Price
- NGVT $53.76
- DNLI $14.99
- Analyst Decision
- NGVT Buy
- DNLI Strong Buy
- Analyst Count
- NGVT 2
- DNLI 15
- Target Price
- NGVT $58.00
- DNLI $33.50
- AVG Volume (30 Days)
- NGVT 218.6K
- DNLI 2.1M
- Earning Date
- NGVT 10-28-2025
- DNLI 11-05-2025
- Dividend Yield
- NGVT N/A
- DNLI N/A
- EPS Growth
- NGVT N/A
- DNLI N/A
- EPS
- NGVT N/A
- DNLI N/A
- Revenue
- NGVT $1,324,800,000.00
- DNLI N/A
- Revenue This Year
- NGVT N/A
- DNLI N/A
- Revenue Next Year
- NGVT $3.95
- DNLI $95,463.19
- P/E Ratio
- NGVT N/A
- DNLI N/A
- Revenue Growth
- NGVT N/A
- DNLI N/A
- 52 Week Low
- NGVT $28.49
- DNLI $10.57
- 52 Week High
- NGVT $60.77
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- NGVT 43.00
- DNLI 57.22
- Support Level
- NGVT $53.93
- DNLI $12.58
- Resistance Level
- NGVT $57.42
- DNLI $15.75
- Average True Range (ATR)
- NGVT 1.54
- DNLI 0.65
- MACD
- NGVT -0.40
- DNLI 0.21
- Stochastic Oscillator
- NGVT 0.23
- DNLI 76.97
About NGVT Ingevity Corporation
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.